Overview

A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)

Status:
Not yet recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company